Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00494338
Status:
TERMINATED
Last Update Posted:
2009-10-01
First Post:
2007-06-28
Brief Title:
Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
due to celecoxib safety issues
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multi-center controlled non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50 reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None